TY - JOUR
T1 - Testicular cancer, version 2.2020
AU - Gilligan, Timothy
AU - Lin, Daniel W.
AU - Aggarwal, Rahul
AU - Chism, David
AU - Cost, Nicholas
AU - Derweesh, Ithaar H.
AU - Emamekhoo, Hamid
AU - Feldman, Darren R.
AU - Geynisman, Daniel M.
AU - Hancock, Steven L.
AU - LaGrange, Chad
AU - Levine, Ellis G.
AU - Longo, Thomas
AU - Lowrance, Will
AU - McGregor, Bradley
AU - Monk, Paul
AU - Picus, Joel
AU - Pierorazio, Phillip
AU - Rais-Bahrami, Soroush
AU - Saylor, Philip
AU - Sircar, Kanishka
AU - Smith, David C.
AU - Tzou, Katherine
AU - Vaena, Daniel
AU - Vaughn, David
AU - Yamoah, Kosj
AU - Yamzon, Jonathan
AU - Johnson-Chilla, Alyse
AU - Keller, Jennifer
AU - Pluchino, Lenora A.
N1 - Publisher Copyright:
© 2019 JNCCN - Journal of the National Comprehensive Cancer Network.
PY - 2019
Y1 - 2019
N2 - Testicular cancer is relatively uncommon and accounts for <1% of all male tumors. However, it is the most common solid tumor in men between the ages of 20 and 34 years, and the global incidence has been steadily rising over the past several decades. Several risk factors for testicular cancer have been identified, including personal or family history of testicular cancer and cryptorchidism. Testicular germ cell tumors (GCTs) comprise 95% of malignant tumors arising in the testes and are categorized into 2 main histologic subtypes: seminoma and nonseminoma. Although nonseminoma is the more clinically aggressive tumor subtype, 5-year survival rates exceed 70% with current treatment options, even in patients with advanced or metastatic disease. Radical inguinal orchiectomy is the primary treatment for most patients with testicular GCTs. Postorchiectomy management is dictated by stage, histology, and risk classification; treatment options for nonseminoma include surveillance, systemic therapy, and nervesparing retroperitoneal lymph node dissection. Although rarely occurring, prognosis for patients with brain metastases remains poor, with .50% of patients dying within 1 year of diagnosis. This selection from the NCCN Guidelines for Testicular Cancer focuses on recommendations for the management of adult patients with nonseminomatous GCTs.
AB - Testicular cancer is relatively uncommon and accounts for <1% of all male tumors. However, it is the most common solid tumor in men between the ages of 20 and 34 years, and the global incidence has been steadily rising over the past several decades. Several risk factors for testicular cancer have been identified, including personal or family history of testicular cancer and cryptorchidism. Testicular germ cell tumors (GCTs) comprise 95% of malignant tumors arising in the testes and are categorized into 2 main histologic subtypes: seminoma and nonseminoma. Although nonseminoma is the more clinically aggressive tumor subtype, 5-year survival rates exceed 70% with current treatment options, even in patients with advanced or metastatic disease. Radical inguinal orchiectomy is the primary treatment for most patients with testicular GCTs. Postorchiectomy management is dictated by stage, histology, and risk classification; treatment options for nonseminoma include surveillance, systemic therapy, and nervesparing retroperitoneal lymph node dissection. Although rarely occurring, prognosis for patients with brain metastases remains poor, with .50% of patients dying within 1 year of diagnosis. This selection from the NCCN Guidelines for Testicular Cancer focuses on recommendations for the management of adult patients with nonseminomatous GCTs.
UR - http://www.scopus.com/inward/record.url?scp=85076271235&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2019.0058
DO - 10.6004/jnccn.2019.0058
M3 - Article
C2 - 31805523
AN - SCOPUS:85076271235
SN - 1540-1405
VL - 17
SP - 1529
EP - 1554
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 12
ER -